Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients

被引：0
|
作者：
Alfonso De Stefano
Chiara Carlomagno
Stefano Pepe
Roberto Bianco
Sabino De Placido
机构：
[1] Università degli Studi di Napoli Federico II,Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词：
Bevacizumab; Arterial hypertension; Metastatic colorectal cancer; Predictive marker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1207 / 1213
页数：6
相关论文
共 50 条
  • [21] Visceral fat as a predictive marker of response to bevacizumab -based treatment in metastatic colorectal cancer.
    Miyamoto, Yuji
    Sakamoto, Yasuo
    Watanabe, Masayuki
    Baba, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: A meta-analysis
    Chen, Cui
    Sun, Peng
    Ye, Sheng
    Weng, Hui-wen
    Dai, Qiang-sheng
    JOURNAL OF BUON, 2014, 19 (04): : 917 - 924
  • [23] Mechanism of bevacizumab-induced arterial hypertension: Relation with skin capillary rarefaction in patients treated for metastatic colorectal cancer
    Morere, J. F.
    Des Guetz, G.
    Mourad, J.
    Levy, B. I.
    Breau, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Chromosome 18q11.2 loss as a predictive marker for response to bevacizumab in metastatic colorectal cancer
    Ylstra, B.
    Cordes, M.
    Biesma, H. D.
    Verheul, H. M.
    Neerincx, M.
    Koopman, M.
    Punt, C. J.
    Meijers, G. A.
    Murphy, V.
    Barat, A.
    Betge, J.
    Ebert, M.
    Gaiser, T.
    Fender, B.
    Klinger, R.
    Das, S.
    Smeets, D.
    Lambrechts, D.
    Byrne, A. T.
    Van Grieken, N. C. T.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S29 - S29
  • [25] Bevacizumab associated calcifications might be a prognostic marker in patients with metastatic colorectal cancer.
    Zhou, Yuwen
    Meng, Qiu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] CT texture analysis as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab
    Shih-Hsin Chen
    Julien Edeline
    Kai-Keen Shiu
    Sarah Benafif
    Sofia Wong
    Ashley Groves
    John Bridgewater
    Balaji Ganeshan
    Cancer Imaging, 15 (Suppl 1)
  • [27] Bevacizumab in elderly patients with metastatic colorectal cancer
    Sclafani, Francesco
    Cunningham, David
    JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (01) : 78 - 88
  • [28] TREATMENT WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Cherciu, Nelly
    Petria, Cristina
    ANNALS OF ONCOLOGY, 2012, 23 : 92 - 92
  • [29] TREATMENT WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ocvirk, Janja
    Rebersek, Martina
    Benedik, Jernej
    Volk, Neva
    ANNALS OF ONCOLOGY, 2011, 22 : v96 - v96
  • [30] Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer
    Hompes, D.
    Ruers, T.
    EJSO, 2011, 37 (09): : 737 - 746
12345